Vahh Chemicals Ltd. IPO (BSE SME)
IPO dates: 4–8 Jun 2026 | Listing: 11 Jun 2026 
Price band: ₹60 (fixed price) | Issue size: ₹13.45 Cr (Fresh: ₹13.45 Cr | OFS: ₹0 Cr) 
Lot size: 2,000 shares | Exchange: BSE SME 
Quick take: Chemical manufacturing company with working capital, a new manufacturing facility in Surat, and loan repayment planned from issue proceeds. Key debate is whether profitability and leverage improvements can sustain in a small fixed-price SME issue.

What the company does

Business: Vahh Chemicals manufactures chemicals and related products.
Wins with: fixed price SME positioning, manufacturing capacity, and B2B supply relationships.
Growth driver: incremental working capital, new manufacturing facility at Surat, and debt repayment.
Key metric: ROE, ROCE, debt/equity, and margin stability.

How it makes money

Primary: Revenue from chemical manufacturing and sales.
Secondary: Capacity expansion and product mix improvements through the new facility.
Single line: The business earns by manufacturing and selling chemical products to customers in its sector.

Financials that matter

What changed:

• Revenue and profit are both tracking higher versus prior years.

• ROE and profitability ratios are strong, though the business remains small and leveraged.

• Financials support the view that the issue is priced against a strong recent run-rate.

IPO structure & signal check

Signal: This is a fully fresh issue with proceeds directed to operations, capex, and debt reduction.

Valuation context

At fixed price ₹60:
Market cap: about ₹50.46 Cr pre/post structure shown in issue data is inconsistent across sources; use the IPO page’s issue math and financial ratios instead.
GMP: about ₹9 reported in market coverage.
Review view: the issue is described as fully priced on recent bumper earnings and aggressive on other parameters.
Valuation Q: whether the company can sustain its strong margin profile as it expands the Surat facility and uses more working capital.

Differentiators

• Strong recent ROE and ROCE.

• Fresh capital for growth, working capital, and debt reduction.

• Fixed-price SME issue with simple capital structure.

• Margin profile is currently healthy relative to size.

Key risks

• Profitability: the recent earnings jump may not sustain.

• Balance sheet: debt/equity is still meaningful.

• Execution: the new Surat facility must deliver quickly.

• Working capital: incremental working capital needs are central to the plan.

Post-listing watchlist

Track over 2–4 quarters:

• Growth: revenue and PAT run-rate after listing.

• Margins: whether EBITDA and PAT margins hold.

• Cash flow: working capital deployment and debt repayment progress.

• Balance sheet: leverage trend after fresh issue utilization.

• Execution: commissioning and scaling of the new facility.

Closing:
This IPO is a bet on chemical manufacturing capacity, working capital support, and debt cleanup. The main question is whether the current earnings strength can persist after the business scales further.